Manuka Honey Inhibits Human Breast Cancer Progression in Preclinical Models

Area of Science:

• Oncology
• Natural Product Chemistry
• Cell Biology

Background:

• Manuka honey (MH) has shown potential antitumor properties in preclinical cancer models.
• Understanding the efficacy and mechanisms of natural compounds like MH is crucial for developing novel cancer therapies.

Purpose of the Study:

• To investigate the in vitro and in vivo antitumor activity of Manuka honey against human breast cancer cells.
• To explore the molecular pathways, including AMPK/AKT/mTOR and STAT3 signaling, affected by MH treatment.

Main Methods:

• In vitro studies using human breast cancer cell lines (MCF-7, MDA-MB-231) and non-malignant mammary epithelial cells (HMECs).
• Assessment of cell proliferation, apoptosis (PARP activation), and signaling pathway activation (AMPK, AKT, mTOR, STAT3).
• In vivo studies involving the administration of MH to nude mice bearing established MCF-7 tumors.

Main Results:

• MH significantly inhibited MCF-7 cell proliferation in a dose-dependent manner, with effects comparable to tamoxifen.
• MH treatment induced apoptosis in MCF-7 cells and activated AMPK while inhibiting AKT/mTOR signaling.
• In vivo, MH significantly reduced tumor volume by 84% in mice with established MCF-7 tumors.

Conclusions:

• Manuka honey exhibits potent antitumor activity against human breast cancer cells, both in vitro and in vivo.
• MH's mechanisms involve inducing apoptosis, activating AMPK, inhibiting AKT/mTOR, and reducing STAT3 phosphorylation.
• Further research into MH for cancer chemoprevention and treatment is warranted.